Ad26.COV2.S, mRNA Boosters Immunogenic After Ad26.COV2.S
Compared with homologous booster, heterologous booster with mRNA-based vaccine yielded larger increase in binding antibodies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.